

Ontario Public Drug Programs

Drug Submission Status

Report for July 2017

Complete Streamlined Multiple-Source

Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Emtricitabine-Tenofovir	Truvada	emtricitabine & tenofovir disoproxil fumarate	200mg/300mg	tablet	02452006
Apotex Inc.	Apo-Doxylamine/B6	Diclectin	doxylamine succinate and pyridoxine HCl	10mg/10mg	FC DR tablet	02413248
Mylan Pharmaceuticals	Mylan-Pregabalin	Lyrica	pregabalin	25mg	capsule	02382210
Mylan Pharmaceuticals	Mylan-Pregabalin	Lyrica	pregabalin	50mg	capsule	02382229
Mylan Pharmaceuticals	Mylan-Pregabalin	Lyrica	pregabalin	75mg	capsule	02382237

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Mylan Pharmaceuticals	Mylan-Pregabalin	Lyrica	pregabalin	150mg	capsule	02382245
Mylan Pharmaceuticals	Mylan-Pregabalin	Lyrica	pregabalin	300mg	capsule	02382253
Ranbaxy Pharmaceuticals Canada Inc.	Ran-Gliclazide MR	Diamicron MR	gliclazide	60mg	ER tablet	02439328
Sandoz Canada Inc.	Sandoz Gliclazide MR	Diamicron MR	gliclazide	30mg	ER tablet	02461323
Sandoz Canada Inc.	Sandoz Gliclazide MR	Diamicron MR	gliclazide	60mg	ER tablet	02461331